Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 23, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - February 23, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

2/23/17 - 83% of Older Voters Want Medicare to Negotiate Drug Prices, Says Survey by the Senior Citizens League
Some 83 percent think Medicare should negotiate prescription drug prices for the Part D program. "The public thinks Medicare should negotiate drug prices just like the agency does for all other medical goods and services," says TSCL's Medicare and Social Security policy analyst, Mary Johnson. A complete repeal of the Affordable Care Act, known as
2/23/17 - Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit
Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, announced today that on February 14, 2017, the plaintiff voluntarily dismissed the putative securities class action lawsuit he had recently filed against the company and certain members of its...
2/23/17 - Achaogen Announces Achievement of a Key Milestone in Developing a Plazomicin Assay to Support Therapeutic Drug Management (TDM) [Tehran Times (Iran)]
-Achaogen, Inc., a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant gram-negative infections, today announced that they have achieved a strategic milestone in their ongoing efforts to develop an assay enabling therapeutic drug management of plazomicin. Achaogen is developing plazomicin for...
2/23/17 - Actinium Pharmaceuticals Announces Active Presence at the BMT Tandem Meetings
Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that the Company is attending the BMT Tandem Meetings, the combined annual meetings of the American Society of Blood and Marrow Transplantation and the Center for International Blood
2/23/17 - AmpliPhi Biosciences Establishes Scientific Advisory Board and Appoints Dr. Timothy Lu of MIT and Broad Institute as SAB Chairman
AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based therapies to treat drug-resistant bacterial infections, announces the formation of its Scientific Advisory Board and the appointment of Timothy K. Lu, M.D., Ph.D., as Chairman of the SAB. In 2017, AmpliPhi plans to initiate phage therapy studies in severa
2/23/17 - Analyst Downgrades ANI Pharmaceuticals (NASDAQ:ANIP) Stock Gets Downgraded By Roth Capital from Buy to Neutral
Analyst Ratings For ANI Pharmaceuticals (NASDAQ:ANIP) Today, ANI Pharmaceuticals (NASDAQ:ANIP) stock was downgraded by Roth Capital from Buy to Neutral with a price target of $69.00. There are 2 hold ratings, 3 buy ratings, 1 strong buy rating on the stock. The current consensus rating on ANI Pharmaceuticals (NASDAQ:ANIP) is Buy (Score: 2.83) with
2/23/17 - Aphios Pharma to Develop FDA-Approved, Cannabis-Based Drugs for Opioid Addiction, Epilepsy and Multiple Sclerosis [Sudan Tribune]
-Aphios Corporation today announced that it is spinning-off Aphios Pharma to develop FDA- approved, cannabis-based drugs for treating highly unmet Central Nervous System disorders such as opioid addiction, epilepsy including childhood epilepsy and multiple sclerosis that are only partially and anecdotally addressed by medical marijuana.
2/23/17 - Ask The Doctors
DEAR DOCTOR: I had my thyroid removed because of papillary cancer, and my surgeon has advised me to take high levels of vitamin D. He says there may be a correlation between low vitamin D levels and the development of cancer and Alzheimer's disease. If I remember correctly, the normal blood range for vitamin D is between 30 and 60 nanograms per mil
2/23/17 - Auris Medical and King`s College London Extend Tinnitus Collaboration [Press TV (Iran)]
-Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced the extension of its collaboration with King`s College London. Professor David E. Thurston of the Institute of Pharmaceutical Science is leading the team at King`s to develop and opti
2/23/17 - BeyondSpring Clinical Data for Lead Asset, Plinabulin, Accepted for Oral Presentation at IASLC's 2017 Targeted Therapies of the Treatment of Lung Cancer
BeyondSpring Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company's clinically and statistically significant data for its innovative lead asset, Plinabulin, has been accepted for oral presentation at this year's International...
2/23/17 - Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck's KEYTRUDA (pembrolizumab)
Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera s Imprime PGG in combination with the Merck anti-PD-1 therapy, KEYTRUDA , in patients with either advanced melanoma who have progressed on treatment with a checkpoint inhibitor therapy, or with TNBC whose disease has
2/23/17 - Blog Coverage Ocular Therapeutix Announced FDA Acceptance of NDA Resubmission for its Product for the Treatment of Ocular Pain
LONDON, UK/ ACCESSWIRE/ February 23, 2017/ Active Wall St. blog coverage looks at the headline from Ocular Therapeutix, Inc. as the Company announced on February 22, 2017, that the Company's New Drug Application resubmission for DEXTENZA?, for the treatment of ocular pain occurring after ophthalmic surgery has been accepted as a filing for review
2/23/17 - Cadila Healthcare receives approval from USFDA [India Infoline News Service]
Cadila Healthcare has received approval from US Food& Drug Administration to initiate Phase II clinical studies of Saroglitazar Magnesium in patients suffering from Primary Biliary. Cadila Healthcare has received approval from US Food& Drug Administration to initiate Phase II clinical studies of Saroglitazar Magnesium in patients suffering from...
2/23/17 - CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Programmed Death-1 antibody, CBT-501, at ASCO-SITC Clinical Oncology Symposium
The data were presented in a poster at the American Society of Clinical Oncology Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium being held from February 23 25, 2017 in Orlando, Florida. The strong in-vivo preclinical data suggest that CBT-501 may have clinical benefit in a variety of tumor types, said Sanjeev Red
2/23/17 - Cellceutix Phase 2 Brilacidin Trial Progresses to Highest Dose Cohort for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis [All Iraq News Agency (AIN)]
-Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, today announced progression of its ongoing Phase 2 clinical trial of Brilacidin to the third cohort for induction of remission of mild-to-moderate ulcerative colitis after..
2/23/17 - China Exclusive: Chinese affordable lung cancer drug hits market [Philippines News Agency]
Its release ends an almost decade-long monopoly by Iressa, developed by British multinational biopharmaceutical company AstraZeneca and introduced to China in 2005.. Yiruike was approved for marketing by China's State Food and Drug Administration after Iressa's patent protection expired in April 2016, Qilu sources said. The drug is a much-needed fi
2/23/17 - Chrysalis BioTherapeutics Initiates $5.45 Million Contract With NIH For Nuclear Countermeasure Development
By a News Reporter-Staff News Editor at Politics& Government Week- Chrysalis BioTherapeutics, Inc. announced initiation of a three-year $5.45 million contract with the National Institute of Allergy and Infectious Diseases to develop TP508 as a countermeasure to increase survival and reduce delayed effects of an accidental or intentional nuclear..
2/23/17 - Corbus Pharmaceuticals Announces Preclinical Data Demonstrating JBT-101 Reduces Inflammation in Alveolar Macrophages from Cystic Fibrosis Patients
Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Michael Knowles, M.D., a member of the Company's Scientific Advisory Board and Professor of Pulmonary and Critical Care Medicine, University of North Carolina Chapel Hill will pre
2/23/17 - CTI BioPharma to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017
CTI BioPharma Corp. today announced that management plans to report its fourth quarter and full year 2016 financial results on Thursday, March 2, 2017, after the close of the U.S. financial markets. Thursday, March 2 1:30 p.m. PT/ 4:30 p.m. ET/ 10:30 p.m. CET 1-877-719-9788 +1 719-325-4802. CTI BioPharma Corp. is a biopharmaceutical company focus
2/23/17 - Curemark Announces Further Expansion of Clinical Sites For Its Phase 3 Clinical Trial for Children with Autism The Blm Study
Curemark, LLC announced today that the Blm Study, a Phase 3 clinical trial to evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at three new sites. Joan Fallon, founder and CEO of Curemark. "Making our clinical trial available to as many children across the United States as possible, is an important ste
2/23/17 - Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported top-line results from the pivotal Phase 3 SEAMLESS study in elderly patients aged 70 years or older with newly diagnosed acute myeloid le
2/23/17 - Diagnostic Imaging Market Worth 36.43 Billion by 2021
According to a new market research report " Diagnostic Imaging Market by Product, MRI, Ultrasound, CT, Nuclear Imaging), Application (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers)- Global Forecast to 2021", published by MarketsandMarkets, the report studies the global market over the forecast period of 2016 to 2021. The
2/23/17 - Dr. Daniel Spyker, Former FDA acting Deputy Division Director of Cardiovascular, Respiratory, and Neurological Devices, Joins NDA Partners [Sudan Tribune]
In Dr. Spykers accomplished career, he held positions as Senior Director of Drug Safety and Pharmacovigilance at Alexza Pharmaceuticals; Director, Pharmacokinetics and Pharmacodynamic Sciences, Genentech, where he established the clinical pharmacology unit; and Senior Medical Director, Clinical Risk Assessment and Coordination Department at Purdue.
2/23/17 - Earth Science Tech Initiates its Cannabis Cannabinoid-Based Composition of its 2 New Pharmaceutical Drugs and 3 Nutraceutical Patent Studies
Earth Science Tech, Inc., an innovative biotech company focused on hemp cannabinoid research and development, has begun composition work on its two new Cannabis Cannabinoid-Based pharmaceutical drugs and has initiated patent studies on its three new nutraceutical products. This is the first project Earth Science Tech and its wholly owned subsidia
2/23/17 - EDITORIAL: No debate needed on drug prices [Mail Tribune, Medford, Ore.]
Feb. 22 There is plenty of distance between Democrats and Republicans over health coverage Republicans want to dismantle the Affordable Care Act, Democrats want to keep it, and those in both parties who want to fix it can't begin to agree on how. Even President Donald Trump says price-gouging pharmaceutical companies are "getting away with murd
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415